DRG Market Assessment reports
Access comprehensive market intelligence covering Disease Landscape & Forecast, Epidemiology Intelligence, Biosimilars Intelligence, China In-depth and more.
Acute Musculoskeletal Pain – Epidemiology – Epidemiology – Acute Musculoskeletal Pain – Mature markets
Clarivate Epidemiology’s coverage of acute musculoskeletal pain (AMP) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States…
Metabolic Dysfunction-Associated Steatohepatitis – Geographic Focus: China – Nonalcoholic Steatohepatitis – China In-Depth (China)
Nonalcoholic steatohepatitis (NASH) is a chronic illness that induces significant and sometimes fatal liver fibrosis; it is one of the primary causes of liver transplantation. In China, where the…
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2023
The approval of the immune checkpoint inhibitors Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) for recurrent and metastatic disease has transformed the SCCHN therapy market, which is…
Dry and Wet Age-Related Macular Degeneration – Special Topics – Special Topics: Gene Therapies in Ophthalmology (US)
The wet age-related macular degeneration (AMD) market in the United States is replete with intravitreal (IVT) therapies—including Regeneron’s Eylea, Roche / Genentech’s Lucentis and Vabysmo,…
Alzheimer’s Disease – Special Topics – Special Topics: Physician Awareness, Perceptions, and Use of Leqembi (US)
Eisai / Biogen’s Leqembi (lecanemab) gained accelerated and full FDA approval in 2023 based on positive clinical and biomarker outcomes from the Phase 3 CLARITY-AD trial. With the U.S. CMS…
Crohn’s Disease – Access & Reimbursement – Access & Reimbursement – Impacts of Biosimilar Adalimumab Launches in Autoimmune Disease (US)
2023 marks a pivotal year for the autoimmune space as numerous releases of biosimilar adalimumab challenge the market dominance of AbbVie’s Humira, one of the best-selling brands in the United…
